On Tuesday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -8.09% from the last session, before settling in for the closing price of $1.36. Price fluctuations for ZNTL have ranged from $1.01 to $13.24 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -3.49% at the time writing. With a float of $54.10 million, this company’s outstanding shares have now reached $71.28 million.
The extent of productivity of a business whose workforce counts for 166 workers is very important to gauge. In terms of profitability, gross margin is 98.56%, operating margin of -283.57%, and the pretax margin is -245.74%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 24.66%, while institutional ownership is 87.65%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -3.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.56% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.28 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
The latest stats from [Zentalis Pharmaceuticals Inc, ZNTL] show that its last 5-days average volume of 0.71 million was inferior to 1.49 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 24.41%. Additionally, its Average True Range was 0.12.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 8.18%, which indicates a significant decrease from 13.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.88% in the past 14 days, which was lower than the 105.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5986, while its 200-day Moving Average is $2.7636. Now, the first resistance to watch is $1.3100. This is followed by the second major resistance level at $1.3700. The third major resistance level sits at $1.4100. If the price goes on to break the first support level at $1.2100, it is likely to go to the next support level at $1.1700. The third support level lies at $1.1100 if the price breaches the second support level.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,952K shares outstanding in the company with a market cap of 89.76 million. Presently, the company’s annual sales total 67,430 K according to its annual income of -165,840 K. Last quarter, the company’s sales amounted to 26,870 K and its income totaled -47,470 K.
